Literature DB >> 15732445

Carisoprodol intoxications and serotonergic features.

Jørgen G Bramness1, Jørg Mørland, Hanne Kristin Sørlid, Nina Rudberg, Dag Jacobsen.   

Abstract

The symptoms and signs of carisoprodol intoxications do not resemble those caused by its metabolite meprobamate. Meprobamate most probably produces its effects through the GABAergic neurotransmitter system. The signs and symptoms of carisoprodol intoxications, however, are not easily explained by interaction with this neurotransmitter system. In the present study, four cases of carisoprodol intoxications are presented with emphasis on the presence of serotonergic signs and symptoms. All four cases fulfilled three different sets of criteria for the diagnosis of serotonin syndrome. These findings could indicate that an increased serotonin level in the central nervous system could explain some of the symptoms and signs of carisoprodol intoxications. This may have implications for the clinical evaluation and treatment of such intoxications. Since few laboratories routinely screen for carisoprodol it is important to keep this drug in mind when encountering intoxications displaying serotonergic symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15732445     DOI: 10.1081/clt-45020

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  8 in total

1.  Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.

Authors:  Gudrun Høiseth; Jørgen G Bramness; Asbjørg S Christophersen; Jørg Mørland
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

2.  Overdose of meprobamate: plasma concentration and Glasgow Coma Scale.

Authors:  Anne-Claire Buire; Fabien Vitry; Guillaume Hoizey; Denis Lamiable; Thierry Trenque
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

3.  Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-08-23       Impact factor: 3.533

4.  Carisoprodol tolerance and precipitated withdrawal.

Authors:  Michael B Gatch; Jacques D Nguyen; Theresa Carbonaro; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2011-11-04       Impact factor: 4.492

5.  CYP2C19 genetics in fatal carisoprodol intoxications.

Authors:  Gudrun Høiseth; Umair Majid; Jørg Mørland; Jørgen G Bramness; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

6.  The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Margaretha Gulliksen; Harald Breilid; Vidar M Steen; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

7.  Carisoprodol abuse in Texas, 1998-2003.

Authors:  Mathias B Forrester
Journal:  J Med Toxicol       Date:  2006-03

8.  Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.

Authors:  Lorie A Gonzalez; Michael B Gatch; Cynthia M Taylor; Cathy L Bell-Horner; Michael J Forster; Glenn H Dillon
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.